03 May 2026
Pure Global: Brazil's AI MedTech Shock—Navigating ANVISA's New Data Rules.
LATAM MedTech Insights
About
This week, we dissect the immediate fallout from Brazil's surprise new regulation, ANVISA RDC 925/2026. This sudden rule change for AI-powered medical software has blindsided many international MedTech companies, creating significant new hurdles for entry into Latin America's largest market.
We explore how the mandate for local Brazilian clinical data and stringent LGPD-aligned cybersecurity protocols is forcing companies to scrap their existing market access strategies. This isn't just another piece of red tape. it's a fundamental shift that could delay product launches by more than a year and add millions to the cost.
**Featured Case:**
Imagine a promising MedTech scale-up, armed with FDA clearance and a robust set of clinical data from the US. Their plan for a quick Brazilian launch is abruptly halted by the new ANVISA rule. Their "gold-standard" clinical data is now deemed insufficient, and their global cybersecurity framework is non-compliant. They now face a critical decision: invest in a costly, time-consuming local trial and data-system overhaul, or abandon the market entirely.
**Key Questions Answered in This Episode:**
* How does ANVISA's new rule redefine "sufficient" clinical data for AI medical devices?
* What specific LGPD cybersecurity measures are now mandatory for your SaMD to be approved in Brazil?
* Can you leverage your existing FDA or CE marking to fast-track any part of the new process?
* What is the most common blind spot for foreign companies when interpreting these new requirements?
* How can you turn this regulatory hurdle into a strategic advantage in the LATAM market?
* Does this new resolution signal a wider protectionist trend across other Latin American markets?
Navigating the complexities of global MedTech regulations is our expertise. Pure Global offers end-to-end regulatory consulting solutions, combining local expertise with advanced AI and data tools to streamline your market access. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit us at https://pureglobal.com/ for a strategic consultation.
We explore how the mandate for local Brazilian clinical data and stringent LGPD-aligned cybersecurity protocols is forcing companies to scrap their existing market access strategies. This isn't just another piece of red tape. it's a fundamental shift that could delay product launches by more than a year and add millions to the cost.
**Featured Case:**
Imagine a promising MedTech scale-up, armed with FDA clearance and a robust set of clinical data from the US. Their plan for a quick Brazilian launch is abruptly halted by the new ANVISA rule. Their "gold-standard" clinical data is now deemed insufficient, and their global cybersecurity framework is non-compliant. They now face a critical decision: invest in a costly, time-consuming local trial and data-system overhaul, or abandon the market entirely.
**Key Questions Answered in This Episode:**
* How does ANVISA's new rule redefine "sufficient" clinical data for AI medical devices?
* What specific LGPD cybersecurity measures are now mandatory for your SaMD to be approved in Brazil?
* Can you leverage your existing FDA or CE marking to fast-track any part of the new process?
* What is the most common blind spot for foreign companies when interpreting these new requirements?
* How can you turn this regulatory hurdle into a strategic advantage in the LATAM market?
* Does this new resolution signal a wider protectionist trend across other Latin American markets?
Navigating the complexities of global MedTech regulations is our expertise. Pure Global offers end-to-end regulatory consulting solutions, combining local expertise with advanced AI and data tools to streamline your market access. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit us at https://pureglobal.com/ for a strategic consultation.